CRDL - Cardiol Therapeutics Inc. Net Sales Margin

Cardiol (CRDL) - corporate logo

Cardiol Therapeutics (CRDL) develops unique formulas to combat rare cardiological pathologies, leveraging patent protection. Annual net margins confirm this trajectory, with the value stabilizing at 0.00. However, the risk of drug adaptation by industry behemoths persists, and the lack of stable revenue streams leaves the business dependent on existing cash reserves.

cardiolrx.com (CRDL) Net Profit Rate: for the period 07/04/2022 - 11/20/2026

Analytical breakdowns for cardiolrx.com (CRDL)

- share price and expert price forecast:
Comprehensive company analysis:Cardiol, CRDL
Manufactured product of Cardiol Therapeutics

Sales margin is calculated as the ratio of net income to total revenue, determining the efficiency of converting revenue into capital. This indicator demonstrates the share of final earnings in every ruble received, revealing internal business imbalances. For Cardiol Therapeutics (CRDL), this parameter reflects the monetization potential of its pericarditis drug development. Patent protection of the molecule minimizes competition, ensuring the stability of future revenues. By analyzing the net sales margin trend, an investor assesses the issuer's real operational efficiency.